Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + bevacizumab in advanced solid tumors
CTR20210801Phase 2Completed
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, bevacizumab in Nonhematologic neoplasms, sponsored by Suzhou Sundia Biotech Co., Ltd.. Started Apr 2021; status: completed.
02
Drugs
retlirafusp alfabevacizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20210801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210801.